Well-differentiated neuroendocrine tumors of the esophagus

Well-differentiated neuroendocrine tumors of the esophagus are exceptionally rare neoplasms within the spectrum of neuroendocrine neoplasms of the gastrointestinal tract. Most esophageal cases reported in the literature are poorly differentiated, high-grade forms, whereas well-differentiated tumors represent a much smaller proportion and are often detected incidentally or during investigation of nonspecific symptoms. The rarity of this entity makes it difficult to define its epidemiology, predisposing factors and natural history, requiring a clinical approach based on established principles for digestive-tract neuroendocrine tumors adapted to the esophageal setting.

From a biological and pathologic perspective, diagnosis requires rigorous distinction among a well-differentiated neuroendocrine tumor (NET), a poorly differentiated neuroendocrine carcinoma (NEC) and mixed forms, because degree of differentiation and proliferation determine prognosis and treatment strategy more strongly than anatomic site alone. In the esophagus, where the clinical presentation may overlap with that of squamous cell carcinoma or adenocarcinoma, confirmation is obtained by endoscopy with biopsy and neuroendocrine immunohistochemical characterization, integrating assessment of Ki-67 and the mitotic index to establish grade according to international classifications.

When possible, treatment aims at local control through endoscopic or surgical resection for limited disease, whereas advanced tumors are managed with systemic strategies used for gastroenteropancreatic NETs, with particular attention to somatostatin receptor expression and selection among somatostatin analogues, peptide receptor radionuclide therapy and targeted options. Multidisciplinary management is crucial at every stage because the rarity of the tumor increases the risk of diagnostic underestimation, suboptimal treatment and inadequately structured follow-up.

The epidemiology of well-differentiated neuroendocrine tumors of the esophagus is dominated by their extreme rarity. The literature therefore consists mainly of case reports, small series and systematic reviews of tumors historically classified as esophageal “carcinoids.” This scarcity of data limits accurate estimation of incidence and prevents robust definition of demographic determinants. Overall, esophageal neuroendocrine tumors are uncommon compared with NETs of the small intestine, pancreas and appendix, and well-differentiated forms are an even smaller subgroup within the esophageal category.

The distal esophagus, near the esophagogastric junction, is the site most often reported for esophageal “carcinoid” tumors, although the disease can theoretically arise anywhere along the organ. Presentation in adulthood is most common, with considerable variability related to lesion size, depth of invasion and local complications. Diagnosis may be delayed because initial symptoms are nonspecific and are often attributed to gastroesophageal reflux disease, esophagitis or dyspepsia.

The etiologic causes have not been defined. No exposure has been shown to be necessary and sufficient for the development of a well-differentiated esophageal NET. In the absence of a known etiology, risk factors can only be discussed as possible associations supported by a generally low level of evidence. A role for chronic inflammatory esophageal conditions or alterations in the mucosal microenvironment has been hypothesized but is not supported by robust causal evidence, and no risk profile useful for targeted preventive interventions can be constructed.

In summary, epidemiology is characterized by extremely small numbers and potential heterogeneity in historical classification; risk factors remain nonspecific, and the clinical priority is correct histologic classification and grading rather than identification of predisposing determinants.

There are no screening programs or population-surveillance strategies for well-differentiated neuroendocrine tumors of the esophagus. The main reason is their extreme rarity, which would make any screening intervention inefficient and unsustainable even with highly sensitive endoscopic techniques. In addition, no noninvasive test with adequate diagnostic performance specific to this entity is available.

In clinical practice, detection occurs through a pathway guided by symptoms or alarm features warranting endoscopy, such as progressive dysphagia, unexplained weight loss, anemia or gastrointestinal bleeding. In this setting, endoscopy is not performed to screen for a NET but as an appropriate assessment of organic esophageal disease. When a well-differentiated neuroendocrine tumor is diagnosed, it is often the result of biopsies obtained from subepithelial, nodular or ulcerated lesions.

Surveillance after treatment is a separate issue. In the absence of site-specific protocols, follow-up is individualized according to extent, grade, resectability, somatostatin receptor status and the treatment performed. The aim is early detection of local recurrence, lymph-node progression or distant metastases through integration of clinical assessment, imaging and, when appropriate, endoscopic surveillance.

Overall, the most rational approach is timely diagnosis based on appropriate indications for endoscopy and follow-up tailored to individual risk after treatment, avoiding standardized schedules unsupported by evidence for such a rare disease.

The biology of well-differentiated neuroendocrine tumors of the esophagus fits within the general framework of neuroendocrine neoplasms (NENs) of the digestive tract, in which the distinction between differentiation and proliferative grade is central. Well-differentiated NETs show organoid architecture, relative cytologic uniformity and retained features of neuroendocrine differentiation, whereas poorly differentiated neuroendocrine carcinomas exhibit marked pleomorphism, extensive necrosis and very high proliferation. In the esophagus, this distinction has a decisive clinical impact because it radically affects the choice between locoregional approaches and aggressive systemic strategies.

The most plausible cellular origin is linked to rare neuroendocrine cell populations in the mucosa and, especially, in the submucosal esophageal glandular structures, with possible neoplastic transformation within a microenvironment influenced by local factors. However, because esophageal NETs are exceptionally rare, site-specific pathogenesis remains poorly defined. At the molecular level, well-differentiated gastroenteropancreatic NETs have documented alterations involving cell-cycle control, signaling pathways and epigenetic regulation, but direct extrapolation to the esophageal site must be cautious and supported by characterization of the individual case, particularly in advanced disease when treatment decisions may depend on biomarkers or receptor features.

Histologically, well-differentiated NETs show trabecular, insular or glandular patterns, with typical “salt-and-pepper” chromatin and a variable amount of vascularized stroma. Grade is defined by the mitotic index and Ki-67, which should be assessed in “hot spots” using standardized methods because grading errors may lead to inappropriate treatment choices. It is also essential to distinguish a well-differentiated NET G3 from an NEC, as both have high proliferation but differ in morphology, biology and treatment sensitivity.

Immunophenotype and markers useful for confirming neuroendocrine nature and defining grade

• Positivity for synaptophysin and, with variable frequency, chromogranin A, supporting neuroendocrine differentiation.
• Expression of INSM1 in many neuroendocrine tumors, particularly useful when chromogranin expression is weak or focal.
• Assessment of Ki-67 and mitotic count to define proliferative grade and prognostic stratification.
• Exclusion panels as required to distinguish squamous cell carcinoma, adenocarcinoma, GIST, lymphoma and metastases.

Overall, pathogenesis is less well defined than at other digestive sites because of the scarcity of cases, but the conceptual framework is that of digestive NENs: the combination of neuroendocrine differentiation, proliferative grade and local invasion pattern determines clinical behavior, metastatic risk and the probability of response to different treatment options.

The clinical manifestations of well-differentiated neuroendocrine tumors of the esophagus are generally nonspecific and often indistinguishable from those of other esophageal disorders. The most common presentation is dysphagia, initially intermittent and later progressive, particularly when the lesion narrows the lumen or alters local motility. Odynophagia, heartburn and reflux symptoms may also occur, often leading to an initial attribution to benign disease and consequent diagnostic delay.

Weight loss may occur and reflects both reduced food intake due to dysphagia and the systemic impact of the neoplasm, especially when disease is more extensive. Retrosternal pain, regurgitation and aspiration-related respiratory symptoms may occur in some cases. Bleeding is less typical than at other sites, but superficial ulceration may cause anemia or hematemesis, particularly in larger or more fragile lesions.

Classic functional syndromes of NETs, such as carcinoid syndrome, are generally rare at this site and become more plausible in the presence of hepatic metastatic disease with systemic mediator secretion, an exceptional scenario in well-differentiated esophageal NETs. In advanced stages, symptoms may result from mediastinal lymph-node involvement or distant metastases, with dyspnea, persistent cough, bone pain or marked fatigue.

Clinical presentations that most often lead to endoscopy and biopsy

• Progressive or persistent dysphagia, with or without weight loss.
• Odynophagia or retrosternal pain not explained by benign causes.
• Heartburn and reflux symptoms with alarm features or failure to respond to treatment.
• Anemia or upper gastrointestinal bleeding, particularly when associated with focal endoscopic findings.
• Regurgitation and aspiration-related respiratory symptoms in the presence of significant stenosis.

Physical examination may reveal no specific findings in early stages; in advanced disease, signs of malnutrition, dehydration, sarcopenia or metastatic involvement may appear. Clinical features alone do not reliably point to a neuroendocrine histologic subtype, making endoscopic and histologic confirmation and correct grade determination essential.

The diagnostic work-up for well-differentiated neuroendocrine tumors of the esophagus begins with suspicion of organic esophageal disease and proceeds sequentially toward endoscopic identification of the lesion, histologic confirmation with determination of differentiation and grade, and functional and anatomic radiologic staging. Clinical suspicion typically arises in the presence of progressive dysphagia, weight loss, retrosternal pain or signs of bleeding, particularly when alarm features coexist.

The cornerstone first-line investigation is esophagogastroduodenoscopy, ideally using high-definition equipment and careful assessment of the esophagus. Lesions may appear nodular, polypoid or subepithelial, sometimes with superficial ulceration. It is essential to obtain multiple, adequately deep biopsies because neuroendocrine tumors may arise in or extend into the submucosa, and a superficial sample may be nondiagnostic or underestimate grade.

Definitive diagnosis is pathologic and requires integration of morphology and immunohistochemistry. Synaptophysin and chromogranin A support neuroendocrine differentiation, whereas Ki-67 and mitotic count define grade. Distinguishing a well-differentiated NET from a poorly differentiated NEC is a critical step because it radically changes treatment and prognosis. When histology suggests a neuroendocrine neoplasm, a possible non-neuroendocrine component should also be assessed because mixed neoplasms require specific classification and may follow different treatment principles.

Endoscopic ultrasonography plays an important role in completing local and locoregional assessment because it estimates depth of wall invasion and characterizes suspicious lymph nodes, with fine-needle aspiration when this would guide management. Anatomic staging is generally based on contrast-enhanced CT of the chest and abdomen, supplemented by MRI if liver lesions are uncertain.

Functional imaging is particularly important in well-differentiated NETs. Detection of somatostatin receptors by 68Ga-DOTATATE PET or equivalent techniques helps define disease extent, select candidates for somatostatin analogues or peptide receptor radionuclide therapy, and guide biopsy of distant sites. 18F-FDG PET may be useful when proliferative grade is high or more aggressive biological behavior is suspected because FDG uptake tends to correlate with proliferation and risk of progression.

In summary, diagnosis is established through endoscopy and adequate biopsy, immunohistochemical confirmation of neuroendocrine differentiation, accurate grading with Ki-67 and mitotic count, assessment of local invasion by endoscopic ultrasonography when indicated, and systemic staging with anatomic and functional imaging, with early multidisciplinary discussion.

Staging of well-differentiated neuroendocrine tumors of the esophagus is complex because there is no universally adopted, site-specific system, and TNM classifications developed for esophageal carcinomas do not fully reflect NET biology. In clinical practice, disease extent must therefore be described by systematically integrating three dimensions: local extension within the wall and adjacent structures, regional lymph-node involvement and distant metastases, using anatomic and functional imaging for a complete representation.

A central prognostic factor, often more informative than site alone, is proliferative grade according to international classifications of digestive-tract neuroendocrine tumors. Grade guides the estimated risk of progression, probability of metastasis and treatment choice and should be explicitly reported together with differentiation.

Proliferative grade of digestive-tract NETs, also applied to the esophageal site

• NET G1: low grade, with a mitotic index below 2 per 2 mm² and Ki-67 below 3%.
• NET G2: intermediate grade, with a mitotic index between 2 and 20 per 2 mm² and Ki-67 between 3% and 20%.
• Well-differentiated NET G3: high proliferative grade with retained differentiation, a mitotic index above 20 per 2 mm² and/or Ki-67 above 20%.

In the absence of a dedicated staging system, a practical framework for disease extent remains useful for clear communication and for aligning treatment decisions with actual spread. Although it does not replace an official system, this approach distinguishes potentially curable forms amenable to local treatment from disease requiring a systemic strategy.

Practical classification of disease extent in well-differentiated esophageal NETs

• Localized disease: lesion confined to the esophagus, with limited wall involvement, no evidence of metastases and negative lymph-node assessment on imaging.
• Regional disease: mediastinal or periesophageal lymph-node involvement documented radiologically or cytologically, without distant metastases.
• Metastatic disease: visceral or bone metastases or extra-regional spread, often identified by receptor-based functional imaging and completed with CT or MRI.

Prognosis depends primarily on grade, disease extent, resectability and completeness of resection when performed. In localized well-differentiated NETs, radical treatment can achieve prolonged control, whereas positive lymph nodes or metastases reduce the probability of durable control and shift the objective toward systemic strategies and symptom control. Performance status, nutritional status and the ability to complete integrated treatments substantially influence outcome, particularly when dysphagia causes malnutrition and reduced treatment tolerance.

Treatment of well-differentiated neuroendocrine tumors of the esophagus is guided by extent, grade, depth of invasion and somatostatin receptor expression. The rarity of the site requires adaptation of established principles for digestive-tract NETs while maintaining a realistic objective that may range from cure in limited disease to control of disease and symptoms in advanced stages.

For small localized tumors, particularly when invasion is superficial and endoscopic ultrasonography suggests a low lymph-node risk, endoscopic approaches with curative intent may be considered, including mucosal resection or submucosal dissection, provided clear margins and an adequate specimen for grading and invasion assessment can be obtained. Larger lesions, deeper invasion or suspected lymph-node involvement generally favor a surgical approach, with esophageal resection and regional lymph-node assessment according to oncologic principles of completeness, tailored to risk and the patient's condition.

For unresectable regional or metastatic disease, systemic therapy is the therapeutic mainstay. If the tumor expresses somatostatin receptors, somatostatin analogues are a central option for stabilizing disease and controlling any secretory symptoms, although such symptoms are rare at this site. In the presence of progression and documented receptor expression, peptide receptor radionuclide therapy with radiolabeled somatostatin analogues may be considered in selected patients after careful assessment of renal function and bone-marrow reserve.

In well-differentiated NETs progressing despite analogues, or when the biology suggests a need for different strategies, targeted options such as mTOR inhibitors may be used, selecting patients according to clinical features and evidence available for gastroenteropancreatic NETs. Cytotoxic chemotherapy has a more variable role in well-differentiated NETs and tends to be considered primarily for higher grades or rapid progression, while always maintaining the distinction from NECs, which follow different treatment principles.

Treatment objectives and options according to the clinical setting

• Localized disease: endoscopic or surgical resection with curative intent, with accurate definition of margins, grade and invasion.
• Regional disease: surgery when resectable or a systemic strategy for unresectable disease, with reassessment for possible conversion.
• Receptor-positive metastatic disease: somatostatin analogues, possible peptide receptor radionuclide therapy after progression, and selection for targeted therapies.
• Symptom control: management of dysphagia with endoscopic or nutritional approaches, pain treatment and early integration of supportive care.

Management of dysphagia and nutritional status is often decisive in making the oncologic strategy feasible. Endoscopic dilatation, selected stents and enteral nutrition may be required as bridging measures or ongoing support. In patients with advanced disease, early integration of palliative care improves symptom control and continuity of care without conflicting with antitumor therapies when appropriate.

Follow-up and post-treatment surveillance for well-differentiated esophageal NETs must be individualized because no site-specific protocols exist and rarity limits comparative studies. The strategy is based on serial clinical assessment, nutritional monitoring and periodic imaging to detect local recurrence, lymph-node progression or new metastases.

After treatment with curative intent, follow-up is generally more frequent during the first few years because recurrence risk is higher when the lesion was larger, deeper or had a higher proliferative grade. Surveillance includes assessment for recurrent dysphagia, retrosternal pain, weight loss and signs of malnutrition. Endoscopy may be used selectively according to symptoms, residual anatomy and the possibility of treatable local recurrence, whereas CT or MRI is used for systemic assessment.

In patients with advanced disease receiving systemic therapy, follow-up frequency is tailored to the treatment regimen, disease burden and progression kinetics. Receptor-based functional imaging may be useful in selected settings to reassess receptor expression and guide subsequent choices, while FDG PET may contribute when more aggressive behavior or an increase in proliferative grade emerges.

In all settings, follow-up has two objectives: detecting clinically meaningful progression and preserving esophageal function, nutrition and quality of life by integrating supportive interventions when dysphagia, sarcopenia or treatment-related adverse effects occur.

Long-term quality-of-life considerations in well-differentiated esophageal NETs depend on the interaction among local effects on swallowing, treatment effects and the psychological impact of a diagnosis often perceived as rare and uncertain. Even when disease is controlled, persistent mild dysphagia, reflux, retrosternal pain or the need for dietary adaptations may substantially affect daily life.

After endoscopic or surgical resection, quality of life is influenced by possible stenosis, motility disturbances and anatomic changes, which may require prolonged gastroenterologic follow-up. Nutritional support is often crucial to prevent weight loss, sarcopenia and frailty, particularly in older patients or those with comorbidities. When enteral support is required, the aim is to preserve independence and functional capacity while reducing hospitalizations and complications.

Systemic therapies, even when well tolerated, may leave chronic effects on energy, physical performance and ability to work. In patients who receive peptide receptor radionuclide therapy or targeted therapies, long-term surveillance of bone-marrow, renal and metabolic effects is particularly important, with early specialist involvement when persistent toxicity emerges.

The psychological burden is amplified by rarity and by the perceived lack of “standard” pathways. Clear communication about the rationale for treatment choices, access to psycho-oncologic support and multidisciplinary care reduce anxiety about progression and promote adaptation. Overall, quality of life requires active, continuous management that combines oncologic control with nutritional support, functional rehabilitation and care of treatment sequelae.

Complications of well-differentiated neuroendocrine tumors of the esophagus result mainly from local effects on luminal patency, possible lymph-node or metastatic spread and treatment consequences. The most important complication is dysphagia with progressive reduction in food intake, which may lead to malnutrition, sarcopenia and dehydration, directly affecting treatment tolerance and practical prognosis. Ulcerated or traumatized lesions may cause bleeding and anemia, although less often than other digestive neoplasms.

In advanced disease, metastases may cause pain, organ dysfunction and general deterioration. Aspiration-related respiratory complications may occur in patients with significant stenosis or regurgitation, with a risk of recurrent pneumonia. After endoscopic or surgical procedures, scar stenosis, infections, anastomotic complications and the need for recanalization or repeat interventions are possible.

• Somatostatin-analogue toxicity: gastrointestinal disturbances, gallstones and glycemic changes requiring clinical monitoring.
• Peptide receptor radionuclide therapy toxicity: myelosuppression, possible nephrotoxicity and risk of late bone-marrow effects, requiring prolonged laboratory surveillance.
• Targeted-therapy toxicity: stomatitis, fatigue, infections, metabolic abnormalities and pulmonary or cutaneous complications that vary by drug.

Prevention and management of complications are based on early nutritional assessment, active treatment of dysphagia, close toxicity monitoring and multidisciplinary integration among oncology, gastroenterology, clinical nutrition and palliative care when necessary. In advanced disease, the objective is to maintain the best possible function, reduce avoidable hospitalizations and ensure continuity of care.